Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365597 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
A Phase 2 study of Urothelial Cancer, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
- 20
- Study locations
NCT02365597 is a Phase 2 study of Urothelial Cancer that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 239 participants, below the 565-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT02365597, a Phase 2 study of Urothelial Cancer, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the objective response rate (complete response \[CR\]+ partial response \[PR\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Metformin
- DRUG Erdafitinib
Study Locations (20)
California
- - Los Angeles
- - Orange
- - Sacramento
- - Stanford
Oregon
- - Medford
- - Tualatin
Pennsylvania
- - Hershey
- - Pittsburgh
Arizona
- - Sedona
Colorado
- - Aurora
District of Columbia
- - Washington D.C.
Illinois
- - Chicago
Iowa
- - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2015-04-22 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365597
The ClinicalTrials.gov registry entry for NCT02365597 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 565-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (58% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Midazolam is the first listed.
NCT02365597 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02365597 about?
NCT02365597 is a clinical study titled "An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer". The purpose of this study is to evaluate the objective response rate (complete response \[CR\]+ partial response \[PR\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
What is the current status of trial NCT02365597?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2015-04-22. Estimated completion is 2027-03-31.
What conditions does trial NCT02365597 study?
This clinical trial studies the following conditions: Urothelial Cancer.
What interventions are being tested in trial NCT02365597?
The interventions under investigation include: Midazolam (DRUG), Metformin (DRUG), Erdafitinib (DRUG).
Who is sponsoring clinical trial NCT02365597?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02365597 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
RECRUITING · Phase 2
-
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RECRUITING · Phase 2
-
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.